Please login to the form below

Not currently logged in
Email:
Password:

Merck acquires US life sciences company

Merck has announced the completion of its acquisition of US life sciences company, Millipore, for $7bn

Germany-based pharmaceutical company, Merck, has announced the completion of its acquisition of US life sciences company, Millipore for a purchase price, including debt and cash, of around $7bn. The companies had agreed the deal in February 2010.

The acquisition's closure follows approval from Millipore's shareholders for the deal which will see the launch of a new division of Merck Chemicals to be called Merck Millipore. Head of Merck Chemicals, Dr Bernd Reckmann, will also assume leadership of Merck Millipore while remaining in his present role.

"The increased breadth of the Merck Millipore product portfolio, together with the expertise of our talented people, will allow us to deepen our customer relationships and gain the new insights we need to further drive innovation," said Dr Reckmann.

"We will also bring together our research and development capabilities, which will make Merck Millipore one of the top three investors in R&D in the Life Science Tools industry. This, in turn, will enable us to create greater value for our customers."

Merck Millipore will be based in Massachusetts, US, with supporting locations throughout the Americas, Europe and Asia-Pacific.

The new division will consist of 10,000 employees in 64 countries, with three business units focusing on bioscience, lab solutions and process solutions.

A range of products, technologies and services for pharma and biotechnology companies to improve productivity in both R&D and manufacturing will be provided by Merck Millipore.

Millipore CEO, Martin Madaus, will not join Merck Millipore but will act as an advisor during the integration process. The majority of this process is expected to be completed by the end of 2010, according to Merck.

15th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics